Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Mar;31(2-3):227-38.
doi: 10.1016/j.cimid.2007.07.009. Epub 2007 Aug 16.

Contagious bovine pleuropneumonia: a rationale for the development of a mucosal sub-unit vaccine

Affiliations
Review

Contagious bovine pleuropneumonia: a rationale for the development of a mucosal sub-unit vaccine

Laurence Dedieu-Engelmann. Comp Immunol Microbiol Infect Dis. 2008 Mar.

Abstract

Contagious bovine pleuropneumonia (CBPP) remains a major cattle disease in Africa with serious socio-economic consequences. Its eradication requires the development of improved vaccines. Knowledge on this disease and its causing agent, Mycoplasma mycoides subsp. mycoides biotype Small Colony (MmmSC), has been progressing significantly in the last years, opening new areas for vaccine design. Advances were achieved in the understanding of the protective immune responses to MmmSC infection and immunopathological mechanisms allowing the pathogen to escape the host immune response. Based on sequencing and genomic studies, some virulence factors and metabolic pathways were unraveled leading to the identification of potential MmmSC vaccine candidates. Based on these findings, this review presents a scientific strategy to design multi-component sub-unit vaccines for mucosal delivery as the most promising approach for efficient long-term protective vaccines to prevent CBPP.

La péripneumonie contagieuse bovine reste une maladie majeure des bovins en Afrique avec de sérieuses conséquences socio-économiques. Son éradication nécessite le développement de vaccins améliorés. Ces dernières années, les connaissances de cette maladie comme de l’agent pathogène responsable, Mycoplasma mycoides subsp. mycoides biotype Small Colony (MmmSC), ont largement évolué, ouvrant la voie à de nouvelles approches vaccinales. Ces avancées ont été obtenues dans la compréhension des réponses immunitaires protectrices face à MmmSC ainsi que des mécanismes immunopathologiques permettant à MmmSC d’échapper à la réponse de l’hôte. De plus, grâce au séquençage et à des études génomiques, certains facteurs de virulence et cycles métaboliques de MmmSC ont été caractérisés permettant l’identification de candidats vaccinaux potentiels. A partir de ces données, cette revue présente une stratégie scientifique pour le développement de vaccins sous-unitaires multi-composants à délivrance mucosale, comme étant l’approche la plus prometteuse pour des vaccins protecteurs à long terme contre la PPCB.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Tambi N.E., Maina W.O., Ndi C. An estimation of the economic impact of contagious bovine pleuropneumonia in Africa. Rev Sci Tech. 2006;25(3):999–1011. - PubMed
    1. Thiaucourt F., Aboubakar Y., Wesonga H., Manso-Silvan L., Blanchard A. Contagious bovine pleuropneumonia vaccines and control strategies: recent data. In: Schudel A., Lombard M., editors. vol. 119. Karger; Dev. Biol. Basel: 2004. pp. 99–111. (Control of infectious animal diseases by vaccination). - PubMed
    1. Thiaucourt F., Dedieu L., Maillard J.C. Contagious bovine pleuropneumonia vaccines, historic highlights, present situation and hopes. In: Brown F., Roth B., editors. vol. 114. Karger; Dev. Biol. Basel: 2003. pp. 111–124. (Vaccines for OIE List A and emerging diseases). - PubMed
    1. March J. Improved formulations for existing CBPP vaccines-recommendations for changes. Vaccine. 2004;22:4358–4364. - PubMed
    1. Van Ginkel F.W., Nguyen H.H., McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis. 2000;6(2):123–132. - PMC - PubMed

MeSH terms